ITGAX and neoplasm: In addition, analysis of myeloid populations revealed increased CD11c+CD8+ antigen-presenting DCs in NOS2/COX2-low tumors from alive patients and indomethacin-treated 4T1 tumor-bearing mice, as well as increased F4/80+MHC II+ antigen-presenting macrophages in the indomethacin-treated 4T1 tumor-bearing mice (Supplemental Figure 4).